157 related articles for article (PubMed ID: 12706937)
1. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure.
Tang WH; Francis GS; Hoogwerf BJ; Young JB
J Am Coll Cardiol; 2003 Apr; 41(8):1394-8. PubMed ID: 12706937
[TBL] [Abstract][Full Text] [Related]
2. Considerations for management of fluid dynamic issues associated with thiazolidinediones.
Hollenberg NK
Am J Med; 2003 Dec; 115 Suppl 8A():111S-115S. PubMed ID: 14678876
[TBL] [Abstract][Full Text] [Related]
3. Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure?
Goltsman I; Khoury EE; Winaver J; Abassi Z
Pharmacol Ther; 2016 Dec; 168():75-97. PubMed ID: 27598860
[TBL] [Abstract][Full Text] [Related]
4. Thiazolidinedione-associated congestive heart failure and pulmonary edema.
Kermani A; Garg A
Mayo Clin Proc; 2003 Sep; 78(9):1088-91. PubMed ID: 12962163
[TBL] [Abstract][Full Text] [Related]
5. The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure.
Aguilar D; Bozkurt B; Pritchett A; Petersen NJ; Deswal A
J Am Coll Cardiol; 2007 Jul; 50(1):32-6. PubMed ID: 17601542
[TBL] [Abstract][Full Text] [Related]
6. Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population-based cohort study in Taiwan.
Hsiao FY; Tsai YW; Wen YW; Chen PF; Chou HY; Chen CH; Kuo KN; Huang WF
Pharmacoepidemiol Drug Saf; 2010 Aug; 19(8):786-91. PubMed ID: 20607752
[TBL] [Abstract][Full Text] [Related]
7. Management of rosiglitazone-induced edema: two case reports and a review of the literature.
Wang F; Aleksunes LM; Reagan LA; Vergara CM
Diabetes Technol Ther; 2002; 4(4):505-14. PubMed ID: 12396745
[TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure.
Granberry MC; Hawkins JB; Franks AM
Am J Health Syst Pharm; 2007 May; 64(9):931-6. PubMed ID: 17468147
[TBL] [Abstract][Full Text] [Related]
9. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
Grossman LD; Parlan G; Bailey AL; Yee G; Yu M; Chan JY
Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
[TBL] [Abstract][Full Text] [Related]
10. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
11. Genetic predisposition and nongenetic risk factors of thiazolidinedione-related edema in patients with type 2 diabetes.
Chang TJ; Liu PH; Liang YC; Chang YC; Jiang YD; Li HY; Lo MT; Chen HS; Chuang LM
Pharmacogenet Genomics; 2011 Dec; 21(12):829-36. PubMed ID: 21934636
[TBL] [Abstract][Full Text] [Related]
12. Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes.
Toprani A; Fonseca V
Diabetes Obes Metab; 2011 Mar; 13(3):276-80. PubMed ID: 21205120
[TBL] [Abstract][Full Text] [Related]
13. [Clinical usefulness of combination treatment with thiazolidinedione and insulin].
Kitamura R; Tanaka Y
Nihon Rinsho; 2001 Nov; 59(11):2233-8. PubMed ID: 11712413
[TBL] [Abstract][Full Text] [Related]
14. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
Patel C; Wyne KL; McGuire DK
Diab Vasc Dis Res; 2005 May; 2(2):61-6. PubMed ID: 16305060
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
Buckingham RE; Hanna A
Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890
[TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone-induced anasarca without heart failure: capillary leakage?
Dagdelen S; Kurt M; Aydin K; Bayraktar M
Hormones (Athens); 2008; 7(2):180-3. PubMed ID: 18477557
[TBL] [Abstract][Full Text] [Related]
17. Metformin and thiazolidinedione use in Medicare patients with heart failure.
Masoudi FA; Wang Y; Inzucchi SE; Setaro JF; Havranek EP; Foody JM; Krumholz HM
JAMA; 2003 Jul; 290(1):81-5. PubMed ID: 12837715
[TBL] [Abstract][Full Text] [Related]
18. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies.
Karalliedde J; Buckingham RE
Drug Saf; 2007; 30(9):741-53. PubMed ID: 17722967
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidinediones in patients with diabetes mellitus and heart failure : implications of emerging data.
Macfarlane DP; Fisher M
Am J Cardiovasc Drugs; 2006; 6(5):297-304. PubMed ID: 17083264
[TBL] [Abstract][Full Text] [Related]
20. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
